查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771501

美国发炎性肠道疾病治疗市场规模、份额、趋势分析报告（按类型、药物类别、给药途径、分销管道、地区、细分市场预测），2025 年至 2030 年

U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 83 Pages | 商品交期: 2-10个工作天内

价格

美国发炎性肠道疾病治疗市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，美国发炎性肠道疾病治疗市场规模预计到 2030 年将达到 157 亿美元，2025 年至 2030 年的复合年增长率为 2.7%。美国溃疡性大肠炎和克隆氏症盛行率的上升预计将在预测期内推动市场成长。发炎性肠道疾病肠道疾病(IBD) 的发展被认为是受遗传易感性、免疫系统功能障碍、环境因素、肠道菌丛失衡和生活方式因素等共同影响的。根据 2023 年发表的一篇论文，发炎性肠道疾病疾病是一种相对常见的慢性病，影响超过 0.7% 的美国人，并且在东北地区最为普遍。患者数量的增加需要先进的治疗方案，从而推动市场成长。

克罗恩病和结肠炎基金会致力于加强产品开发，以改善发炎性肠道疾病患者的生活品质。基金会已推出专门的融资机制「创投」（Ventures），以支持以产品为导向的研发。

2023年9月，武田宣布FDA已接受该公司提交的生技药品核准申请(BLA)，用于皮下注射Entyvio（通用名维多珠单抗），用于治疗克隆氏症。该监管部门的核准为新药、生技药品和医疗设备进入市场铺平了道路。这有望扩大IBD患者的治疗选择，并改善他们的预后和生活品质。

美国发炎性肠道疾病治疗市场报告重点

  • 根据类型，克隆氏症在 2024 年占据了市场主导地位，收入份额最大。这一巨大份额可以归因于对更多治疗方案和进步的需求，因为克隆氏症是一种影响胃肠道的慢性发炎性疾病，会引起腹痛、腹泻、体重减轻和疲劳等症状。
  • 根据药物类别，TNF 抑制剂预计将在 2024 年占据最大的市场收入份额，因为它们能够有效控制症状并抑制发炎。
  • 根据给药途径，注射剂将在 2024 年占据最大的市场占有率。注射药物，例如生技药品和生物相似药，旨在针对参与发炎性肠道疾病发炎过程的特定蛋白质和细胞。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国发炎性肠道疾病治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国发炎性肠道疾病治疗市场：按类型分類的业务分析

  • 2024 年及 2030 年各类型市场占有率
  • 细分仪表板：按类型
  • 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
  • 克隆氏症
  • 溃疡性大肠炎

第五章美国发炎性肠道疾病治疗市场：按药物类别分類的业务分析

  • 2024 年及 2030 年各药品类别的市场占有率
  • 细分仪表板：依药物类别
  • 2018 年至 2030 年药品类别市场规模、预测与趋势分析
  • 氨基水杨酸盐
  • 皮质类固醇
  • TNF抑制剂
  • 白血球介素抑制剂
  • 抗整合素
  • JAK抑制剂
  • 其他的

第六章美国发炎性肠道疾病治疗市场：依给药途径分類的业务分析

  • 2024 年和 2030 年按给药途径分類的市场占有率
  • 细分仪表板：依给药途径
  • 2018 年至 2030 年按给药途径分類的市场规模、预测和趋势分析
  • 口服
  • 注射

第七章美国发炎性肠道疾病治疗市场：通路业务分析

  • 2024 年和 2030 年按分销管道分類的市场占有率
  • 细分仪表板：按分销管道
  • 2018 年至 2030 年分销通路市场规模、预测与趋势分析
  • 医院药房
  • 零售药局
  • 网路药局

第八章美国发炎性肠道疾病治疗市场：按地区分類的估计和趋势分析

  • 2024 年及 2030 年各地区市场占有率分析
  • 市场仪表板：按地区
  • 2018-2030年各地区市场规模及预测趋势分析
  • 西
    • 主要地区趋势
    • 目标疾病的盛行率
    • 法律规范
    • 报销框架
  • 中西部
    • 主要地区趋势
    • 目标疾病的盛行率
    • 法律规范
    • 报销框架
  • 东北
    • 主要地区趋势
    • 目标疾病的盛行率
    • 法律规范
    • 报销框架
  • 西南
    • 主要地区趋势
    • 目标疾病的盛行率
    • 法律规范
    • 报销框架
  • 东南
    • 主要地区趋势
    • 目标疾病的盛行率
    • 法律规范
    • 报销框架

第九章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Biogen
    • Novartis AG
    • Eli Lilly and Company
    • UCB SA
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.
Product Code: GVR-4-68040-286-7

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 15.70 billion by 2030 and is projected to grow at a CAGR of 2.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

  • Based on type, the Crohn's disease segment dominated the market in 2024 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
  • Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2024 due to their effectiveness in managing the symptoms and reducing inflammation.
  • Based on route of administration, the injectable segment held the largest market share in 2024. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Inflammatory Bowel Disease Treatment market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Crohn's Disease
    • 4.4.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 4.5. Ulcerative Colitis
    • 4.5.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Aminosalicylates
    • 5.4.1. Aminosalicylates Market, 2018 - 2030 (USD Million)
  • 5.5. Corticosteroids
    • 5.5.1. Corticosteroids Market, 2018 - 2030 (USD Million)
  • 5.6. TNF Inhibitors
    • 5.6.1. TNF Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.7. IL inhibitors
    • 5.7.1. IL inhibitors Market, 2018 - 2030 (USD Million)
  • 5.8. Anti-integrin
    • 5.8.1. Anti-integrinMarket, 2018 - 2030 (USD Million)
  • 5.9. JAK inhibitors
    • 5.9.1. JAK inhibitors Market, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacy
    • 7.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 8.4. West.
    • 8.4.1. Key Country Dynamics
    • 8.4.2. Target Disease Prevalence
    • 8.4.3. Regulatory Framework
    • 8.4.4. Reimbursement Framework
    • 8.4.5. West U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Midwest
    • 8.5.1. Key Country Dynamics
    • 8.5.2. Target Disease Prevalence
    • 8.5.3. Regulatory Framework
    • 8.5.4. Reimbursement Framework
    • 8.5.5. Midwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Northeast
    • 8.6.1. Key Country Dynamics
    • 8.6.2. Target Disease Prevalence
    • 8.6.3. Regulatory Framework
    • 8.6.4. Reimbursement Framework
    • 8.6.5. Northeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Southwest
    • 8.7.1. Key Country Dynamics
    • 8.7.2. Target Disease Prevalence
    • 8.7.3. Regulatory Framework
    • 8.7.4. Reimbursement Framework
    • 8.7.5. Southwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Southeast
    • 8.8.1. Key Country Dynamics
    • 8.8.2. Target Disease Prevalence
    • 8.8.3. Regulatory Framework
    • 8.8.4. Reimbursement Framework
    • 8.8.5. Southeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Biogen
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Novartis AG
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Eli Lilly and Company
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. UCB S.A.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck & Co., Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Johnson & Johnson Services, Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. inflammatory bowel disease market revenue estimates and forecast by type, 2018 - 2030 (USD Million)
  • Table 4 Prevalence of Crohn's Disease in the U.S. (Per 100,000)
  • Table 5 Prevalence of Ulcerative Colitis in the U.S. (Per 100,000)
  • Table 6 U.S. inflammatory bowel disease market revenue estimates and forecast, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Key corticosteroid drugs used in the U.S. for IBD treatment
  • Table 8 Key drugs with their description included in others segment
  • Table 9 U.S. inflammatory bowel disease market revenue estimates and forecast, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 Key oral medications approved for IBD
  • Table 11 U.S. inflammatory bowel disease market revenue estimates and forecast by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Key players undertaking mergers and acquisitions
  • Table 13 Key players undertaking partnerships and collaborations
  • Table 14 Key players undertaking new product launches
  • Table 15 Other strategies taken up by the market players

List of Figures

  • Fig. 1 U.S. inflammatory bowel disease market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Type and drug class segment snapshot
  • Fig. 11 Route of administration and distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market value, 2024 (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTEL analysis
  • Fig. 17 U.S. Inflammatory bowel disease market: Type outlook and key takeaways
  • Fig. 18 U.S. Inflammatory Bowel Disease market: Type movement analysis
  • Fig. 19 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. inflammatory bowel disease market: Drug class outlook and key takeaways
  • Fig. 22 U.S. inflammatory bowel disease market: Drug class movement analysis
  • Fig. 23 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 TNF inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 IL inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Anti-integrin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. inflammatory bowel disease market: Route of administration outlook and key takeaways
  • Fig. 31 U.S. inflammatory bowel disease market: Route of administration movement analysis
  • Fig. 32 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. inflammatory bowel disease market: Distribution channel outlook and key takeaways
  • Fig. 35 U.S. inflammatory bowel disease market: Distribution channel movement analysis
  • Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Market participant categorization
  • Fig. 40 Company heat map analysis
  • Fig. 41 Strategic framework